ReBio Pharma Announces the formation of a Scientific Advisory Board
Turku, Finland, 01 December 2020 - Rebio Technologies Oy (“ReBio Pharma”, “ReBio” or the “Company”), today announced today the formation and members of its Scientific Advisory Board (SAB), comprised of leaders in ophthalmology and ophthalmic drug delivery, chaired by Professor Arto Urtti, Ph.D. The SAB will work cohesively with management to advance and expand the Company’s development pipeline.
“I’m delighted to be appointed Chair of ReBio’s Scientific Advisory Board, and to be part of such a distinguished and comprehensive group of ophthalmic drug development experts,” said Dr. Urtti. “Collectively, we will look to guide ReBio through the development of its current pipeline while exploring the potential of ReBio’s exciting sustained release platform.”
“The establishment of the Scientific Advisory Board marks a significant step for ReBio, as we transition from the research stage to clinical development. The prestigious and complementary group of scientific thought leaders we have assembled to sit on our Scientific Advisory Board will provide ReBio with relevant and informed counsel in the years to come as we continue our research efforts and further the development of our clinical pipeline,” said Jonathan Glen, founder and acting CEO of ReBio. “Each member brings unique experience from clinical, non-clinical, pharmacologic, and pharmaceutical development of ophthalmic therapeutics. I believe this panel will serve us well as we transform ReBio into a clinical stage biotechnology company.”
The founding members of the ReBio Scientific Advisory Board are:
Professor Arto Urtti, Ph.D. – Professor of Biopharmaceutics at the University of Eastern Finland, Director of the Centre for Drug Research, University of Helsinki
Peter Adamson, Ph.D. – Professor, Institute of Ophthalmology, University College London; Formerly VP/Head of Ophthalmology Research, GlaxoSmithKline
Dr. Hari Jayaram, MRCOphth, Ph.D. – Deputy Director, Glaucoma Service, and Co-Chair, Research Management Committee, Moorfields Eye Hospital (NHS) London.
Olli Oksala Ph.D. – co-inventor of latanoprost for the treatment of glaucoma; specialist in ophthalmic pharmaceutical development; Formerly Director of Scientific Affairs, Santen Pharmaceutical Co., Ltd.; Head of Ophthalmological Research, Oy Leiras Takeda.